Inbec治疗艾滋病效果如何？

How effective is Inbec in treating AIDS? Let’s find out together below. Five months after Inbec was officially approved by the China Food and Drug Administration (CFDA), the British pharmaceutical company GlaxoSmithKline (GSK) announced that its joint venture ViiV Healthcare's new anti-AIDS drug Inbec was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. This time Inbec uses DTG, an integrase inhibitor, as the core drug, and a treatment plan with two backbone drugs, abacavir and lamivudine, and makes it into a single-tablet treatment for promotion, making the core drug a great improvement in HAART treatment.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance. In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, Inbec, which uses DTG integrase inhibitors as its core, has proven to be controllable in terms of drug safety.

In addition, Inbec treatment can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.